INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5438 participants.
Also called NCT03871517
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,438 participants
- Sponsor
- Registry
-
NCT03871517
-
- Other papers using this trial's data
- Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03871517. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2022-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
- Condition
- Ischemic Stroke
- Condition
- Indobufen
- Condition
- Aspirin
- Intervention (Drug)
- Indobufen
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct03871517- Content hash
ef6a2ef082ade717883af57326e1a727481e04dae36bb35281bb883b75881ce8